MET and thyroid gland carcinoma: For example, in BRAF (V600E)–mutant thyroid cancer cells, treatment with the BRAF inhibitor PLX4032 was partially ineffective because of overexpression of c-Met, which in turn activated the PI3K/Akt and MAPK pathways (98).